[1]Von Schweinitz D. Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg, 2012, 21(1): 21-30 [2]Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis, 1999, 19(3): 271-285 [3]Raney B. Hepatoblastoma in children: a review. J Pediatr Hematol Oncol, 1997, 19(5): 418-422 [4]Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol, 2013, 14(9): 834-842 [5]Han ZG. Mutational landscape of hepatoblastoma goes beyond the Wnt-beta-catenin pathway. Hepatology, 2014, 60(5): 1476-1478 [6]Jia D, Dong R, Jing Y, et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology, 2014, 60(5): 1686-1696 [7]López-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol, 2009, 40(6): 783-794 [8]Liu P, Calvisi DF, Kiss A, et al. Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development. Oncotarget, 2017, 8(43): 73433-73447 [9]Sylvester KG, Colnot S. Hippo/YAP, β-catenin, and the cancer cell: a "menage a trois" in hepatoblastoma. Gastroenterology, 2014, 147(3): 562-565 [10]Tao J, Calvisi DF, Ranganathan S, et al. Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology, 2014, 147(3): 690-701 [11]Yu FX, Zhao B, Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell, 2015, 163(4): 811-828 [12]Wang Y, Yu A, Yu FX. The Hippo pathway in tissue homeostasis and regeneration. Protein Cell, 2017, 8(5): 349-359 [13]Gu Y, Zhang L, Yu FX. Functions and regulations of the Hippo signaling pathway in intestinal homeostasis, regeneration and tumorigenesis. Yi Chuan, 2017, 39(7): 588-596 [14]Nusse R, Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell, 2017, 169(6): 985-999 [15]Morrone S, Cheng Z, Moon RT, et al. Crystal structure of a Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate recruitment. Proc Natl Acad Sci U S A, 2012, 109(5): 1500-1505 [16]Mariotti L, Pollock K, Guettler S. Regulation of Wnt/beta-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding. Br J Pharmacol, 2017, 174(24): 4611-4636 [17]Campbell CI, Samavarchi-Tehrani P, Barrios-Rodiles M, et al. The RNF146 and tankyrase pathway maintains the junctional Crumbs complex through regulation of angiomotin. J Cell Sci, 2016, 129(18): 3396-3411 [18]Callow MG, Tran H, Phu L, et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One, 2011, 6(7): e22595 [19]Wang W, Li N, Li X, et al. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. Cell Rep, 2015, 13(3): 524-532 [20]Ma L, Wang X, Jia T, et al. Tankyrase inhibitors attenuate WNT/beta-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget, 2015, 6(28): 25390-25401 [21]Hong Y, Manoharan I, Suryawanshi A, et al. β-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells. Cancer Res, 2015, 75(4): 656-665 [22]Liu G, Yu FX, Kim YC, et al. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. Oncogene, 2015, 34(27): 3536-3546 [23]Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell, 2012, 150(4): 780-791 [24]Park HW, Kim YC, Yu B, et al. Alternative Wnt Signaling Activates YAP/TAZ. Cell, 2015, 162(4): 780-794 [25]Szenker-Ravi E, Altunoglu U, Leushacke M, et al. RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6. Nature, 2018, 557(7706): 564-569 [26]Doi I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gan, 1976, 67(1): 1-10 |